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Latent transforming growth factor-β binding proteins are a family of extracellular matrix proteins comprising four isoforms (LTBP-1, -2, -3, -4)
with different structures, tissue expression patterns and affinity for TGF-β. So far, respective knockout models have highlighted some essential
functions for LTBP-2, LTBP-3 and LTBP-4, while the physiological significance of LTBP-1 is only superficially known. Here we report for the
first time the generation and characterization of a mouse model lacking both the long and short LTBP-1 isoform. Surprisingly, respective mice are
viable and fertile. However, detailed X-ray analysis of the skull revealed a modified facial profile. In addition, the gene disruption induces a
reduced biological activity of TGF-β that became evident in an experimental model of hepatic fibrogenesis in which the LTBP-1 knockout animals
were less prone to hepatic fibrogenesis. Furthermore, comparative cDNA microarray gene expression profiling of cultured hepatic stellate cells
confirmed that respective nulls were less receptive to cellular activation and transdifferentiation into myofibroblasts. Therefore, we conclude that
LTBP-1 has essential functions in the control of TGF-β activation.
© 2007 Elsevier B.V. All rights reserved.Keywords: LTBP-1; Microarray; Stellate cells; Liver fibrogenesis1. Introduction
Transforming growth factor-β proteins (TGF-βs) are
secreted signalling molecules with multifunctional activities.
They were initially identified as growth factors that regulate
proliferation, differentiation, migration and apoptosis. Further-
more, TGF-βs induce the deposition of extracellular matrix
(ECM) proteins. In mammals, three different TGF-β isoformsAbbreviations: α-SMA, α-smooth muscle actin; ECM, extracellular matrix;
EGF, epidermal growth factor; ES, embryonic stem cells; FCS, fetal calf serum;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HBSS, Hank's buffered
saline solution; HRP, horse radish peroxidase; HSC, hepatic stellate cell(s); Ko,
knockout(s); LAP, latency associated protein; Ltbp-1/-2/-3/-4, genes encoding
the LTBP-1/-2/-3/-4 proteins; LTBP, latent transforming growth factor-β
binding protein; TGF-β, transforming growth factor-β; Wt, wild type(s)
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doi:10.1016/j.bbamcr.2007.08.004(TGF-β-1,-2,-3) are known. They are secreted in high mole-
cular weight complexes as inactive (latent) precursors in which
the mature TGF-β dimer is non-covalently associated with its
N-terminal residue, the latency-associated protein (LAP) [1,2].
This small latent complex is disulfide bonded to the glyco-
sylated latent TGF-β binding protein (LTBP) thereby forming
the large latent complex. Four different Ltbp genes have been
isolated that have different affinities for TGF-β [3–6].
LTBPs belong to the fibrillin superfamily, a group of high
molecular weight matrix proteins comprising several epidermal
growth factor (EGF)-like and characteristic 8-cysteine repeats
(8-Cys). Whereas the EGF-like repeats mediate the interaction
with other proteins, the N-terminal hinge region and parts of the
C-terminal region bind to the ECM [7,8]. The covalent asso-
ciation of the small latent complex takes place via the third 8-
Cys repeat [6,9]. This entire composition allows LTBPs to target
TGF-β to the ECM and control its bioavailability but the precise
mechanisms of TGF-β activation are currently unknown. In
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was shown to be responsible for the proteolytic cleavage of
mature TGF-β from the latent complex [10]. In addition,
thrombospondin-1 can activate TGF-β by inducing a confor-
mational rearrangement [11]. Moreover, it was hypothesized
that the interaction of LTBP-1 with components of the ECM and
the binding of LAP to αvβ6 integrin is necessary for proper
activation of TGF-β [12,13]. Once activated, TGF-β initiates
signalling by assembling receptor complexes and phosphory-
lation of downstream Smad transcription factors [14].
The Ltbp-1 gene was first cloned from human foreskin
fibroblasts [15]. It is expressed in variable amounts in different
tissues and the occurrence of two independent promoters, alter-
native splicing, and differential proteolytic processing mediate
the synthesis of a variety of gene products [16–22]. Compared
to the short form (LTBP-1S), the long form (LTBP-1L) com-
prises an N-terminal extension that is responsible for a more
efficient interaction with the ECM. Molecular cloning of the
murine Ltbp-1 revealed that this gene has an overall organi-
zation that is similar to the Ltbp-2 gene [19] and is expressed
almost ubiquitously in the heart, lung, spleen, kidney, stomach,
placenta, prostate gland, testis, and liver [22].
LTBP-1 and TGF-β are key factors in wound healing and
fibrosis. Altered production of TGF-β has been implicated in the
pathogenesis of atherosclerosis, cancer, autoimmune and inflam-
matory diseases, keloid formation, hypertrophic scarring and
organ fibrosis. Exemplarily, the functionality of TGF-β1 in
hepatic fibrosis is well documented. In this process, hepatic
stellate cells (HSC) become activated and transdifferentiate into
myofibroblasts (MFB) that express large quantities of ECM
components [23]. Several factors have been shown to play an
important role in the promotion and establishment of the trans-
differentiated phenotype including paracrine and autocrine
stimulatory growth factor loops, oxidative stress, chemokines,
and other soluble factors. Therefore, the knowledge of LTBP-1
functionality in controlling and regulation of the concentration of
biologically active TGF-β is crucial for the understanding of
hepatic fibrogenesis.
In previous studies, gene disruption of Ltbp-2, Ltbp-3 or Ltbp-
4 resulted in severe phenotypes [24–27]. Mice lacking LTBP-2
die during embryogenesis and disruption of Ltbp-4 resulted in
severe pulmonary emphysema, cardiomyopathy, colorectal can-
cer, and alteration of TGF-β activity [26–28]. In addition, Ltbp-2
and Ltbp-4 nulls showed deficiencies in elastic fiber architecture
[26,27]. The elimination of the Ltbp-3 gene resulted in strong
bone abnormalities triggering the development of osteosclerosis
and osteoarthritis in advanced age [25]. Apart from the decreased
osteoclast functionality causing high bone mass [29], respective
animals further showed an involution of the thymus and spleen
and developed pulmonary emphysema [30,31].
To address the physiological function of LTBP-1, we gen-
erated a knockout (Ko) mouse model in which both Ltbp-1
transcripts (i.e., Ltbp-1L and Ltbp-1S) were inactivated. We
here demonstrate that these Ltbp-1−/− mice are viable and fertile
exhibiting only a mild phenotype with subtle alterations in
facial structures. In addition, comparative gene expression pro-
filing of primary HSC revealed that the loss of LTBP-1 decreasethe expression of genes that are associated with TGF-β activity.
Consistently, we found that respective animals were less prone
to hepatic fibrogenesis when subjected to bile duct ligation. In
summary, we found that the loss of LTBP-1 leads to a decrease
of TGF-β activity suggesting that LTBP-1 is an essential factor
in controlling the overall biological activity of TGF-β.
2. Materials and methods
2.1. Gene targeting
A 7186-bp NcoI/Bst1107I fragment of the murine Ltbp-1 gene (accession no.
AY143161) harbouring exon 5 was subcloned and a lacZ/neo cassette was inte-
grated into the uniqueBspMI site. The resulting targeting vector was transfected by
electroporation into embryonic stem cells (ES) (129 SvJ). ES that had incorporated
the transgene were subsequently maintained on mitotically inactive mouse
embryonic fibroblast feeder layers and selected in the presence of 400 μgG418/ml.
Genomic DNA from 240 neomycin-resistant ES clones was isolated, digestedwith
EcoRI, separated on 1% agarose gels, and transferred to Hybond-N membranes
(AmershamBiosciences,Munich, Germany). For the identification of homologous
recombinants, Southern blots were hybridized with an external gene fragment as a
probe. The ES cell clones that showed correct targeting were injected into C57BL/
6J blastocysts. Subsequently, the compositeswere transferred into pseudo-pregnant
foster mice and resulting chimeras were mated. The congenic strain (N10) was
produced by repeated backcrosses into the C57BL/6J strain.
2.2. Western blot analysis
Cells were washed in ice-cold HBSS and extracted with lysis buffer
[20 mmol Tris–HCl/l (pH 7.2), 150 mmol NaCl/l, 2% (w/v) Nonident P-40,
0.1% (w/v) SDS, 0.5% (w/v) sodium deoxycholate)] containing the Com-
plete™-mixture of proteinase inhibitors (Roche Diagnostics, Mannheim,
Germany). Equal amounts of protein lysates were diluted with Nu-PAGE™
LDS electrophoresis sample buffer without reducing agents, heated at 70 °C for
10 min, and separated in 3–8% Tris–acetate gradient gels (LTBP-1) using Tris–
acetate SDS running buffer (50 mmol Tris–HCl/l (pH 8.2), 50 mmol tricine/l,
and 0.1% (w/v) SDS or 4–12% Bis–Tris gradient gels using buffer MES buffer
(TGF-β1). Proteins were electroblotted onto nitrocellulose membranes, and
equal loading was monitored by Ponceau S staining. Non-specific binding sites
were blocked in PBS containing 5% (w/v) nonfat milk powder and 0.5% (w/v)
bovine serum albumin. LTBP-1 protein was detected with a polyclonal
antiserum Ab-39 (kindly provided by C.-H. Heldin, Uppsala, Sweden) and
Smad2 phosphorylation was determined using antibody PhosphoSmad2 (Ser
465/467; #3101) obtained from Cell Signaling (Boston, MA). The FLAG-
tagged TGF-β1 was detected with antibody ANTI-FLAG M2 (F 3165; Sigma-
Aldrich, Taufkirchen, Germany). As a loading control, the membranes were
probed with a monoclonal β-actin antibody (A5441, Sigma-Aldrich).
2.3. Northern blot analysis
Total RNAwas separated on 1% (w/v) denaturing agarose gels, transferred to
Hybond-N+ membrane (Amersham), and fixed by baking for 2 h at 80 °C.
Hybridization probes specific for prss11 and lcn2were prepared by restriction of
pGEM-T vectors containing the corresponding array gene fragments (Miltenyi
Biotech, Cologne, Germany) and labelled using the random prime labelling
system. Hybridization of the [α-32P]-dCTP-labelled probes and washing of
membranes were carried out essentially as described previously [32]. For internal
control, the blots were rehybridized with a probe specific for GAPDH.
2.4. Cell culture
HSC were isolated from Ltbp-1 nulls and respective C57BL/6J (B6) control
mice according to a methodology established for rats [32]. To obtain sufficient
amounts of HSC, cells isolated from 5 mice each were pooled prior culturing in
DMEM medium containing 5% FCS for 1 day (representing quiescent HSC) to
6 days (representing activated HSC). The mean purity of HSC preparations was
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(GFAP), a specific marker for HSC. Murine skin fibroblasts were isolated from
outgrowths and subcultured for a few passages.
2.5. RNA isolation, amplification and labelling for
microarray hybridization
RNA was isolated using the Nucleospin-II-RNA-Extraction-Kit (Macherey
& Nagel, Düren, Germany). Samples were quantified by spectrophotometry and
RNA integrity was checked by gel electrophoresis (Bioanalyser 2001, Agilent,
Massy, France). RNAwas isolated from pools of cultivated HSC prepared from
5 male animals/mice. Linear amplification of RNA was done using a modified
protocol of a method described previously [33]. Amplified RNA (aRNA) sam-
ples were quantified and analyzed by gel electrophoresis. One microgram of
aRNA from each sample was labelled by reverse transcription with Cy5 and
Cy3 fluorescence and labelled samples were then hybridized on PIQOR™
Immunology Microarrays (Miltenyi Biotec).
2.6. Microarray experiments
Two questions were addressed by gene expression profiling, namely (i) the
difference between activated Ltbp-1−/− and Wt HSC and (ii) the difference
between activated and quiescent HSC. Hybridizations of labelled cDNAs were
conducted in replicates. PIQOR™ Immunology microarrays contain cDNAs of
1070 murine genes spotted as four-fold replicates on different positions of the
array. As a qualitative measurement for the validity of the data and to check for
the uniformity of the hybridization process, the coefficient of variation (CV) of
the four ratios for the respective gene was calculated to 2.59%.
2.7. Array hybridization and data analysis
Hybridization, scanning and data analysis were performed as described in
detail elsewhere [34]. Briefly, image capture and signal quantification ofFig. 1. Organization and disruption of the murine Ltbp-1 gene. (A) The Ltbp-1 gene i
spheroids) located 5′ upstream of exons 1 and 5. The gene directs the synthesis of
disruption a lacZ/neo gene cassette was inserted into the BspMI site of the first comm
verification of successful insertion is depicted as a black line.hybridized PIQOR™ microarrays were done with the Agilent DNA-Microarray
Scanner (INFOS) at 50% laser power and ImaGene software Version 5.0
(BioDiscovery, Los Angeles, CA). Local background was subtracted from the
signal to obtain the net signal intensity and the ratio of Cy5/Cy3. Subsequently,
the mean of the ratios of four corresponding spots representing the same cDNA
was computed. The mean ratios were normalized using locally weighted linear
regression (LOWESS normalization method). For normalization only those
spots were used for which the fluorescent intensity in one of the two channels
was twice the mean background of all unflagged spots. Only genes displaying a
net signal intensity 2-fold higher than the mean background were used for
further analysis. Ratios referred to represent mean values out of two
hybridizations and out of three hybridizations (Wt/nulls HSC), respectively.
Only genes that were detected on at least two arrays were analyzed. Ratios b1
are given as negative reciprocal value. A detailed description of the microarray
platform and the generated data is deposited in the National Center for
Biotechnology Information Gene Expression Omnibus (GEO, accession no.
GSE5670).
2.8. Semi-quantitative RT-PCR experiments
Total RNA was treated with DNAseI according to the manufacturer's
instructions for 20 min at 37 °C to remove traces of genomic DNA. After RNA-
Clean-Up treatment, 1 μg of total RNA was reversely transcribed at 42 °C for
60 min using the Superscript II reverse transcriptase (Invitrogen, Karlsruhe,
Germany) and Oligo-dT primers. Aliquots of the first strand cDNAs were
subjected to PCRwith 200 nM forward and reverse primer, respectively, 200 nM
dNTPs, 1.3 mM MgCl2 and 0.25 U Taq DNA polymerase in 1× PCR buffer.
Cycle conditions were initial denaturation for 90 s at 95 °C; annealing for 30 s at
57 °C; extension for 30 s at 72 °C; denaturation for 30 s at 95 °C. 20–27 cycles
were conducted to assure analysis to take place in the exponential amplification
phase of each respective PCR-product. A final elongation was performed for
5 min at 72 °C. Thereafter, the whole PCR samples were analyzed on 1.5%
TBE-agarose gels. The individual primer sets used (see Supplementary Table 1),
were designed to amplify and clone the respective genes from mouse and rats arranged in 34 exons harbouring two independent promoters (marked by black
two transcripts, i.e., Ltbp-1L and Ltbp-1S, respectively [19,22]. (B) For gene
on exon (exon 5). The localisation of the external hybridization probe used for
Fig. 2. Verification of Ltbp-1 gene disruption. (A) Southern blot analysis
of embryonic fibroblasts taken from Wt (+/+), Ko (−/−) and heterozygous
(+/−) mice. (B) Genomic DNA extracted from mouse tail biopsies was
subjected to PCR using primers specific for the Wt or the Ko allele.
The position of nucleotide size markers is indicated on the left margin.
(C) Protein samples (∼100 μg/lane) of skin fibroblasts of the indicated
phenotypes were analyzed by Western blot for expression of LTBP-1 under
non-reducing conditions using antibody Ab-39. The position of protein
size markers is indicated on the left. Equal protein loading was confirmed
using an antibody directed against β-actin and Ponceau S staining (not
shown).
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2.9. Southern blot analysis
Genomic DNAwas isolated from fibroblasts using standard protocols. Equal
amounts of DNAwere digested by EcoRI and separated on 0.75% (w/v) agarose
gels, transferred to Hybond-N+ membrane, and fixed by baking for 2 h at 80 °C.
The external hybridization probe was similarly prepared as for Northern blot.
2.10. Genotyping
Genomic DNA isolated from tail biopsies of the offspring were genotyped
by PCR using primer combinations L4 5′-d(GAG TAA CCA CAC TGG TCG
CAT C)-3′ and L5 5′-d(CCA CTC GGAAGT TCG TGG CTG TC)-3′ for the Wt
genotype or neo 5′-d(CTG CTC TTTACT GAA GGC TCT TT)-3′ together with
L5 for the Ko genotype.
2.11. Cephalometric analysis
Detached heads of sacrificed mice were laterally X-rayed using a static long
tubular X-ray apparatus (Steliodent 70, Siemens, Munich, Germany). The
exposure (100 ms) was unitary 70 kV and 7 mA. Only pictures with a perfect
overlay of both mandibular rami as a sign for correct orientation of the skulls
were constituted for high-resolution scanning (1200 dpi) and evaluation with a
graphic program adopting cephalometric analysis tools used in humans. The
results were statistically analyzed by multiple linear regression using age, sex,
and genotype as independent variables and 21 cephalometric measurements in
addition to the mandibular bone density as dependent variables. The α-value of
0.05 was adjusted by means of the multiple-comparison correction according to
Bonferroni leading to a probability level of pb0.00227 in each test.
2.12. Bile duct ligation
Four control and threeKomice underwent bile duct obstruction under general
anaesthesia and mice were sacrificed after 4 weeks. The blood was drawn for
serum analysis, and pieces of the livers were fixed in 4% paraformaldehyde for
histological examination or frozen immediately in liquid nitrogen and stored at
−80 °C for protein isolation or hydroxyproline quantification. All experimenta-
tions were approved by the local committee for care and use of laboratory
animals, and performed according to strict governmental and international
guidelines on animal experimentation.
2.13. Determination of hydroxyproline
The content of hydroxyproline in liver samples was determined using a
standard protocol. Briefly, defined quantities of liver samples were subjected to
acidic hydrolysis. Then, the samples were filtered and vaporized. The
concentrated probes were solved in sodium citrate loading buffer and analyzed
in duplicate by HPLC. The statistical significance of the results was analyzed by
Mann–Whitney U test.
2.14. Transfection experiments
CHO cells were transfected using the FuGENE6 transfection reagent
(Roche) with expression vectors pCMV-Tag 4A-hTGF-β1FLAG and/or
hLTBP1S-pcDNA3.1 that were generated by standard cloning procedures.
2.15. Sirius red staining
Collagen content was assessed by Sirius red staining of paraffin-embedded
slices. Briefly, liver sections were deparaffinized and the slides were incubated
for 1 h in a solution of saturated picric acid containing 0.1% Sirius Red 80.
Stained slides were then incubated in 0.01 N HCl for 2 min and washed in
running distilled water, dehydrated, mounted, and examined by light
microscopy.3. Results
3.1. Targeted disruption of the Ltbp-1 gene
A targeting vector was constructed by insertion of a lacZ/
neomycin resistance cassette into the first common exon of the
two Ltbp-1 transcripts (exon 5 of LTBP-1L) (Fig. 1A). After
transfection into ES cells, 240 transformants were screened
by Southern blot using an external hybridization probe re-
sulting in the isolation of two independent clones with proper
insertion of the disruption cassette (Fig. 1B). Cells of the
respective clones were injected into C57BL/6J blastocysts,
transferred into the uteri of pseudopregnant recipients, and
offspring with chimeric coat colour were crossed. F1 hybrids
tested to be heterozygous for the disrupted gene were back-
crossed into the C57BL/6J strain background. To generate
Ltbp-1 nulls, heterozygous animals were interbred and lit-
ters genotyped by Southern blot hybridization (Fig. 2A).
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method discriminating between the Wt and disruption allele
(Fig. 2B).Fig. 3. Craniofacial abnormalities of Ltbp-1 nulls. (A) Head phenotype of Wt and L
analysis of 57 high-resolution dental teeth films. Altered were (i) distance MUK–IUK
(iii) distances MOK–LAOK and MOK–IOK on the maxilla. For more details see Su
sibling controls showing an overall shortening in the Ltbp-1 nulls. The alteration was o
mandible had at the same time reduced sizes of the basisphenoid and basioccipital bTo demonstrate the functionality of the introduced gene
disruption, we performed Western blot analysis revealing
that the LTBP-1 protein was absent in respective Ltbp-1−/−tbp-1 Ko. (B) Significant changed positions on Ko vs. Wt skulls ascertained by
on the mandible, (ii) angle between MOK and A referred to the suture S1, and
pplementary Fig. 1. (C) Representative mandibles of Ltbp-1 nulls and respective
bserved in a small fraction of the nulls. (D) Animals evolving a shortening of the
ones.
Table 1
Statistics of skull parameters of control vs. Ltbp-1 nulls
p-Value
Angle A-S1-C/MOK 0.000080
Distance MOK–LAOK 0.000004
MOK–IOK 0.000003
MUK–IUK 0.000030
Density Mandibular 0.885559
Note. Data are based on multivariance analysis of 22 parameters (angles,
distances, distance ratios, mandible bone density) taken from 57 mandibles. For
abbreviations and location of individual fixed points, see Supplementary Fig. 1.
39F. Drews et al. / Biochimica et Biophysica Acta 1783 (2008) 34–48animals (Fig. 2C). Interestingly, the expression of LTBP-1 in
heterozygous animals was only hardly detectable.
3.2. Viability and phenotype of the Ltbp-1 nulls
The classic Mendelian inheritance ratios were found in mating
of heterozygous animals and moreover, the mating between
homozygous animals resulted in viable and fertile descendants
(not shown). However, phenotypically, homozygous nulls
displayed a more compact head structure with shortened snoutsFig. 4. Comparative analysis of liver fibrogenesis. (A) Bile duct ligation was perform
stained with Sirius Red (upper panel) and α-SMA (lower panel). The analysis reveal
nulls. (B) Hydroxyproline content of liver fromWt and Ko animals that were subjecte
higher in Wt animals ( p=0.05). (C) Protein extracts were prepared from Wt (+/+) an
analyzed by Western blot. Equal gel loading was demonstrated in Ponceau S stain.(Fig. 3A). To characterize this craniofacial abnormality in more
detail, we took high-resolution X-ray images from skulls taken
from animals of different age and gender. We defined seventeen
benchmarks (Supplementary Fig. 1) and measured distances and
angles. Some values were dependent on age but all were inde-
pendent from the gender. In multivariant analysis, three distances
and one angle were significantly (pb0.00227) decreased in the
nulls (Table 1). All of them concerned the frontal region of the
skulls including the maxilla. The angle between the superior first
molar and the nasal bone was diminished and the length of the
maxilla was shortened. Accordingly, the lower front teeth were
distally inclined (Fig. 3B) and the mandible was shortened
(Fig. 3C). Moreover, bone preparations from siblings revealed a
contraction of the basisphenoid, the basisoccipital, and extrem-
ities (Fig. 3D, Supplementary Fig. 2).
3.3. Suppression of liver fibrogenesis in Ltbp-1 nulls
To estimate if mice lacking LTBP-1 protein had altered TGF-β
activity in vivo, we subjected both, Ltbp-1+/+ and Ltbp-1−/− mice
to a surgery that induces hepatic fibrogenesis. In the chosened for 4 weeks and liver slices prepared form Wt (left) and Ko mice (right) were
ed that the deposition of collagen and expression of α-SMAwas lower in Ltbp-1
d to BDL. The analysis revealed that the hydroxyproline content was significant
d Ko (−/−) livers that were subjected to BDL. The Smad2 phosphorylation was
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progress of matrix expression and deposition was comparatively
analyzed. Although the typical blood parameters for bilirubin,
aspartate aminotransferase (AST), and alanine aminotransferase
(ALT) indicating the icteric reactionwere increased between eight
and fifteen times in all mice, comparative Sirius Red staining and
immunohistochemistry of respective liver sections revealed
that the overall deposition of fibrillar collagen and expression of
α-smooth muscle actin (α-SMA) were lower in the Ltbp-1 nulls
(Fig. 4A). Simultaneously, we found that the hydroxyproline
content indicating the amount of collagen was higher in Wt
animals confirming the results of the histochemical stainings
(Fig. 4B). Moreover, in BDL livers the amount of phosphorylated
Smad2 reflecting the overall TGF-β activity was higher in Wt
animals (Fig. 4C).
3.4. Differential gene expression during transdifferentiation
To address the actual role and importance of LTBP-1 for the
biological activity of TGF-β in cultured HSC, we analyzed theFig. 5. Microarray analysis. (A) Representative array (left) and double-log scatterplot (rig
and quiescent (Cy3-labelled) HSC from Wt mice. (B) Representative array (left) and do
activated HSC isolated from Ltbp-1 nulls (Cy5-labelled) and respective Wt control HS
filtering is shown in double logarithmic scale (represented by a dot). x-Axis: Cy3 signa
differential signal intensities. The microarray experiments were performed in duplicate
In order to minimize the influence of individual gene regulation effects, samples for eain vitro transdifferentiation behaviour of Wt and Ltbp-1−/− by
gene expression profiling using cDNA microarrays. This pro-
filing was conducted using the PIQOR™ Immunology Micro-
arrays containing 1070 different genes. Control (same vs. same)
hybridizations with independently amplified and labelled Wt
fibroblast RNAs showed a maximum expression difference of
1.29 fold. 99.99% of the detected genes had less than a 1.2-fold
expression difference (not shown). Therefore, an expression
difference of at least 1.5-fold was considered to be significant.
To monitor the expressional changes during the activation
process, we first compared Wt HSC after one day in culture
(quiescent phenotype) with those cultured for 6 days (activated
phenotype) (Fig. 5A).
The gene expression of “quiescent” and “activated”Wt HSC
in vitro resulted in 1062 detectable signals out of 1070 genes
present on the array. Altogether 460 genes showed a differential
regulation. 266 (57.8%) of the regulated genes differed at least
2-fold and 108 (23.5%) at least 4-fold. There were a couple of
genes upregulated in the quiescent HSC that are implicated in
stress response (e.g., HSPa1b/1a, HSP105, interferon responseht) of a microarray analysis comparing gene expression of activated (Cy5-labelled)
uble-log scatterplot (right) of a microarray analysis comparing gene expression of
C (Cy3-labelled). The signal intensity of each spot/gene which passed the quality
l intensity, y-axis: Cy5 signal intensity. Dashed diagonals define the areas of x-fold
(activated/quiescent WT HSC) and triplicate (activated Ko/Wt HSC), respectively.
ch condition were prepared from cell pools generated from 5 male mice each.
Table 2
Strongest upregulated genes in quiescent HSC hybridized against activated HSC
Gene
symbol
GenBank
accession no.
Gene Ratio activated/quiescent
WT HSC array #40
CV
#40 (%)
Ratio activated/quiescent
WT HSC array #42
CV
#42 (%)
Mean activated/
quiescent WT HSC
hspa1b NM_010479 Heat shock protein-1b −279.95 15 −223.70 10 −248.69
hspa1a NM010478 Heat shock protein-1a
tgfbi NM_009369 Transforming growth factor, β induced −117.35 17 −100.00 5 −107.98
ltbp4 NM_175641 Latent transforming growth
factor-β binding protein 4
−50.00 11 −50.00 12 −50.00
c1qa NM_007572 Complement component 1,
q subcomponent, α polypeptide
−50.00 25 −33.33 38 −40.00
irf1 NM_008390 Interferon regulatory factor 1 −33.33 8 −33.33 3 −33.33
jun NM_010591 jun Oncogene −25.00 1 −25.00 5 −25.00
sparcl1 NM_010097 sparc-like 1 (mast9, hevin) −20.00 8 −20.00 6 −20.00
irf7 NM_016850 Interferon regulatory factor 7 −20.00 5 −16.67 7 −18.18
darc NM_010045 Duffy blood group −16.67 4 −16.67 24 −16.67
lrat NM_023624 Lecithin–retinol acyltransferase
(phosphatidyl-choline-retinol-
O-acyltransferase)
−20.00 5 −14.29 6 −16.67
cxcl10 NM_021274 Chemokine (c-x-c motif) ligand 10 −12.50 4 −14.29 7 −13.33
spry1 NM_011896 Sprouty homolog 1 (Drosophila) −12.50 2 −11.11 3 −11.76
atf3 NM_007498 Activating transcription factor 3 −11.11 8 −12.50 14 −11.76
icam1 NM_010493 Intercellular adhesion molecule −11.11 3 −11.11 10 −11.11
csf1r NM_007779 Colony stimulating factor 1 receptor −11.11 11 −11.11 18 −11.11
myd116 NM_008654 Myeloid differentiation primary
response gene 116
−11.11 14 −11.11 9 −11.11
mapt NM_010838 Microtubule-associated protein tau −9.09 6 −14.29 3 −11.11
bmp2 NM_007553 Bone morphogenetic protein 2 −12.50 14 −10.00 7 −11.11
dcn NM_007833 Decorin −10.00 4 −11.11 2 −10.53
map3k8 NM_007746 Mitogen-activated protein kinase
kinase kinase 8
−11.11 5 −10.00 4 −10.53
lum NM_008524 Lumican −10.00 6 −10.00 3 −10.00
tlr2 NM_011905 Toll-like receptor 2 −10.00 9 −9.09 8 −9.52
hck NM_010407 Hemopoietic cell kinase −11.11 7 −7.69 17 −9.09
c4b;c4a NM_009780 Complement component 4a and b −8.33 47 −10.00 31 −9.09
c1s NM_144938 Complement component 1,
s subcomponent
−9.09 13 −8.33 5 −8.70
egr1 NM_007913 Early growth response 1 −10.00 6 −7.69 15 −8.70
ccl4 NM_013652 Chemokine (c-c motif) ligand 4 −10.00 21 −7.69 26 −8.70
gem NM_010276 gtp Binding protein −11.11 8 −6.67 13 −8.33
sorbs1 NM_009166 Sorbin and sh3 domain containing 1 −7.14 12 −7.14 10 −7.14
emr1 NM_010130 egf-like Module containing mucin-like,
hormone receptor-like sequence 1
−7.14 11 −6.67 14 −6.90
ccl2 NM_011333 Chemokine (c-c motif) ligand 2 −6.67 3 −6.67 3 −6.67
selenbp1 NM_019414 Selenium binding protein 2 −6.25 7 −6.67 3 −6.45
selenbp2 NM_009150 Selenium binding protein-1
c2 NM_013484 Complement component 2 (within h-2s) −7.14 3 −5.88 18 −6.45
socs1 NM_009896 Suppressor of cytokine signaling 1 −6.67 9 −5.56 8 −6.06
irf5 NM_012057 Interferon regulatory factor 5 −6.67 6 −5.56 6 −6.06
tnfsf9 NM_009404 Tumor necrosis factor (ligand)
superfamily, member 9
−6.25 3 −5.56 9 −5.88
nfkbia NM_010907 Nuclear factor of kappa light chain gene
enhancer in b-cells inhibitor, α
−5.88 2 −5.88 5 −5.88
ncoa1 NM_010881 Nuclear receptor coactivator 1 −5.88 3 −5.56 10 −5.71
cd36 NM_007643 CD36 antigen −5.56 3 −5.88 10 −5.71
prkcb1 NM_008855 Protein kinase c, β 1 −5.56 12 −5.26 21 −5.41
plekhc1 NM_146054 Pleckstrin homology domain containing
family c (with ferm domain) member 1
−5.26 10 −5.56 18 −5.41
cxcl9 NM_008599 Chemokine (c-x-c motif) ligand 9 −5.26 4 −5.00 4 −5.13
rgs1 NM_015811 Regulator of G protein signaling 1 −5.56 5 −4.76 2 −5.13
fcgr1 NM_010186 fc Receptor, igg, high affinity i −4.76 9 −5.00 16 −4.88
hsp110 NM_013559 Heat shock protein-110 −5.00 30 −4.76 12 −4.88
bcl2a1a NM_009742 b-Cell leukemia/lymphoma 2
related protein a1a
−5.56 9 −4.35 19 −4.88
cd82 NM_007656 CD82 antigen −4.55 2 −5.00 3 −4.76
fosb NM_008036 fbj Osteosarcoma oncogene b −4.76 7 −4.76 26 −4.76
(continued on next page)
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Table 2 (continued)
Gene
symbol
GenBank
accession no.
Gene Ratio activated/quiescent
WT HSC array #40
CV
#40 (%)
Ratio activated/quiescent
WT HSC array #42
CV
#42 (%)
Mean activated/
quiescent WT HSC
col6a1 NM_009933 Procollagen, type VI, α1 −4.76 2 −4.55 4 −4.65
col16a1 NM_028266 Procollagen, type XVI, α1 −4.55 8 −4.76 9 −4.65
sos2 XM_916574 Son of sevenless homolog 2 (Drosophila) −4.55 7 −4.76 4 −4.65
cxcl12 NM_021704 Chemokine (c-x-c motif) ligand 12 −4.35 4 −5.00 5 −4.65
ptpn6 NM_013545 Protein tyrosine phosphatase,
non-receptor type 6
−4.55 6 −4.35 17 −4.44
fos NM_010234 FBJ osteosarcoma oncogene −4.76 4 −4.00 14 −4.35
itih3 NM_008407 Inter-α-trypsin inhibitor, heavy chain 3 −4.76 7 −4.00 19 −4.35
hgf NM_010427 Hepatocyte growth factor −4.35 3 −4.35 4 −4.35
stat5a NM_011488 Signal transducer and activator
of transcription 5A
−4.35 9 −4.35 8 −4.35
vipr1 NM_011703 Vasoactive intestinal peptide receptor 1 −4.35 5 −4.35 30 −4.35
pla2g7 NM_013737 Phospholipase A2, group VII −4.55 7 −3.85 14 −4.17
Ratios are indicated as fold change. Ratios b1 are given as negative reciprocal values. CV: coefficient of variation of detected replicates on the microarray. The
respective consecutive array numbers are indicated (#40, #42). Mean: mean expression ratios. Due to nb3 δ−values are not denoted.
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plement system) (Table 2). Among the genes, which were found
to be lower expressed in activated cells, some are known as
HSC marker genes including LRAT, the enzyme that catalyzes
the esterfication of retinol to form the characteristic vitamin A
droplets, CD36 (fatty acid-translocase) [35], the proteoglycans
decorin and lumican [36] non fibril-forming collagen type VI-α
chain [37], HGF, Fcgr1 (Fc receptor) and CD74 (MHC-class II
complex invariant polypeptide). Interestingly, Ltbp-4 was
highly expressed in the quiescent cells.
The picture for the genes found to be stronger expressed in
activated cells (lower expressed in quiescent cells) is even more
striking (Table 3). Known markers like Acta2 (smooth muscle
actin), Spp1 (Osteopontin) and genes involved in ECM degra-
dation and synthesis were highly expressed compared to the
quiescent controls including MMP-3, MMP-9, MMP-10, MMP-
13, Serpine1 (PAI-1), Serpinb2 (PAI-2), Serpinh1-2, TIMP-1,
TIMP-2, TIMP-3, THBS1, THBS3, fibrillar Col1A1, and
Fibulin-2. CD9 and CD81, members of the tetraspanin family
known to play a role in hepatic stellate cell motility, and TM4SF1,
another tetraspanin, were also identified to be upregulated upon
activation, as well as the proinflammatory cytokine IL-6.
3.5. Differential gene expression in Wt and Ltbp-1−/− HSC
The comparison of the Ltbp-1−/− and Wt HSC after 6 days of
in vitro activation revealed only slight differences in the ex-
pression pattern (Fig. 5B). Out of 977 detected genes, 40 genes
were differently expressed (Table 4) and only 6 genes showed a
fold change of more than two, the biggest difference observed
was a (−) 3.39-fold change (LRAT).
Although the quantitative expression differences betweenWt
and Ltbp-1−/− HSCwere rather marginal, they allowed to clearly
qualify the HSC that were taken from Ltbp-1−/− as being less
activated than their Wt counterparts using the “transdifferentia-
tion data set” (Wt1d vs. Wt6d) as benchmark to characterize the
respective conditions (see Tables 2 and 3). 11 out of 12 relatively
stronger expressed genes (Ltbp-1 not included) in activated Wt
HSC could be associated with an activated phenotype in thereference data set, while 20 out of 28 regulated genes that were
higher in the nulls were indicative for the quiescent phenotype.
Not surprisingly, out of twelve genes that were higher in the Wt,
Ltbp-1 turned out to be the most differentially expressed gene.
The cellular activation markers PTGS2, TMF4SF1, MMP-10,
MMP-13, and THBD were also among the genes that were
higher expressed in HSC taken from the Wt animals. Strong
markers for the quiescent phenotype (EGR1, HGF, COL6A1,
LUMICAN and LRAT) were found to be higher expressed in
cells taken from Ltbp-1 nulls. Taken together, these observations
implied that the disruption of Ltbp-1 leads to a retention of HSC
transdifferentiation in vitro. Remarkably, all LTBP- and TGF-β
isoforms and receptors analyzed showed no differential
expression in this analysis (Table 5).
3.6. Semi-quantitative RT-PCR and Northern blot analysis
To validate the accuracy of the microarray analysis, we
performed semi-quantitative RT-PCR using the same RNA pools.
β-Actin and RPS6 served as non-regulated control genes. The
differential expression of 5 genes (CLU, LRAT, IFIT1, RDC1,
HGF) that were higher expressed in Ko cells and 2 genes
(Ltbp-1, PTGH2) that were higher expressed in Wt cells were
confirmed by RT-PCR (Fig. 6A). In addition, further Northern
blot experiments with two genes (LCN2 and PRSS11) were exe-
cuted demonstrating that the results obtained in our control arrays
performed with fibroblast RNAs were reproducible (Fig. 6B).
3.7. Physiological function of LTBP-1
To test if LTBP-1 has an impact on TGF-β1 secretion, we
transfected CHO cells with an expression vector encoding a
FLAG-tagged TGF-β1 alone or in combination with an expres-
sion vector for human LTBP-1S (hLTBP-1S). We observed an
enhanced TGF-β1 secretion in cells that were transfected with
both vectors (Fig. 7A). To rule out if the co-transfection of both
plasmids let to a better transfection efficacy, we further included a
control in which cells were double transfected with the TGF-β1
expression vector and a vector expressing the reporter gene GFP.
Table 3
Selection of strongest upregulated genes in activated HSC hybridized against quiescent HSC
Gene
symbol
GenBank
accession no.
Gene Ratio activated/quiescent
WT HSC array #40
CV #40
(%)
Ratio activated/quiescent
WT HSC array #42
CV #42
(%)
Mean activated/
quiescent WT HSC
mmp3 NM_010809 Matrix metallopeptidase 3 49.55 18 44.96 8 47.26
mmp13 NM_008607 Matrix metallopeptidase 13 40.28 9 38.36 25 39.32
spp1 NM_009263 Secreted phospho-protein-1 32.58 31 32.43 17 32.51
timp1 NM_011593 Tissue inhibitor of metalloproteinase 1 24.79 3 24.8 2 24.80
lcn2 NM_008491 Lipocalin 2 25.09 7 19.85 9 22.47
fbln2 NM_007992 Fibulin 2 20.07 4 21.48 8 20.78
thbd NM_009378 Thrombomodulin 25.04 27 15.37 35 20.21
tm4sf1 NM_008536 Transmembrane 4 superfamily member 1 20.73 12 19.29 3 20.01
mmp10 NM_019471 Matrix metallopeptidase 10 23.28 29 15.59 39 19.44
thbs1 NM_011580 Thrombospondin 1 18.96 5 18.55 5 18.76
acta2 NM_007392 Actin, α 2, smooth muscle, aorta 7.48 13 26.85 24 17.17
ptgs2 NM_011198 Prostaglandin-endoperoxide synthase 2 15.72 11 14.12 9 14.92
col5a2 NM_007737 Procollagen, type V, α2 15.02 4 14.49 4 14.76
cd24a NM_009846 CD24a antigen 14.11 22 9.93 13 12.02
ctgf NM_010217 Connective tissue growth factor 13.2 6 10.41 4 11.81
fstl1 NM_008047 Follistatin-like 1 11.75 4 9.68 5 10.72
inhba NM_008380 Inhibin β-a 9.54 20 8.73 14 9.14
col8a1 NM_007739 Procollagen, type VIII, α1 7.69 8 8.36 19 8.03
col7a1 NM_007738 Procollagen, type VII, α1 7.27 20 8.37 11 7.82
serpinb2 NM_011111 Serine (or cysteine) peptidase inhibitor,
clade b, member 2
6.34 5 7.81 24 7.08
stmn1 NM_019641 Stathmin 1 6.78 10 7.36 7 7.07
pmp22 NM_008885 Peripheral myelin protein 6.14 7 7.13 4 6.64
pgf NM_008827 Placental growth factor 4.47 39 8.16 5 6.32
ltb4dh NM_025968 Leukotriene b4 12-hydroxydehydrogenase 5.97 13 6.33 6 6.15
timp3 NM_011595 Tissue inhibitor of metalloproteinase 3 6.18 4 5.96 3 6.07
tnc NM_011607 Tenascin c 5.3 35 6.76 5 6.03
hmox1 NM_010442 Heme oxygenase (decycling) 1 5.28 24 6.13 13 5.71
il6 NM_031168 Interleukin 6 5.51 34 5.38 3 5.45
cd9 NM_007657 CD9 antigen 5.23 8 5.31 6 5.27
bax NM_007527 bcl2-associated x protein 4.91 3 5.25 5 5.08
procr NM_011171 Protein c receptor, endothelial 5.08 18 5.08 10 5.08
serpinh1 NM_009825 Serine (or cysteine) peptidase inhibitor,
clade h, member 1
5.17 8 4.86 2 5.02
p2ry14 NM_133200 Purinergic receptor p2y,
G protein coupled, 14
4.98 2 4.89 7 4.94
itga5 NM_010577 Integrin α 5 (fibronectin receptor α) 4.71 26 5.14 19 4.93
tubb5 NM_011655 Tubulin, β 5 4.86 5 4.92 5 4.89
mgst1 NM_019946 Microsomal glutathione S-transferase 1 4.21 21 4.83 12 4.52
cd44 NM_009851 CD44 antigen 4.41 18 4.56 6 4.49
mapk6 NM_015806 Mitogen-activated protein kinase 6 4.85 10 4.12 4 4.49
col1a1 NM_007742 Procollagen, type I, α1 4.55 6 4.25 5 4.40
hprt1 NM_013556 Hypoxanthine guanine
phosphoribosyl transferase 1
4.34 1 4.37 2 4.36
serpine1 NM_008871 Serine (or cysteine) peptidase inhibitor,
clade E, member 1
4.5 4 4.2 17 4.35
Ratios are indicated as fold change. Ratios b1 are given as negative reciprocal values. CV: coefficient of variation of detected replicates on the microarray. The
respective consecutive array numbers are indicated (#40, #42). Mean: mean expression ratios. Due to nb3 δ-values are not denoted. The full dataset was submitted to
the GEO-Database (GSE5670).
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Western blot using antibody Ab-39 (Fig. 7B).
4. Discussion
LTBPs were first described as ECM proteins with significant
importance for the bioavailability of TGF-β. From gene dis-
ruption studies, a direct or indirect role in the early development
as well as in the tissue differentiation, and bone formation was
suggested for LTBP-2, -3 and -4 [24–27]. In the present study,we have successfully disrupted the gene for both the long and
the short LTBP-1 isoform. The gene disruption was verified by
Southern blot, RT-PCR, and Western blot revealing that the
generated animals are true LTBP-1 knockout mice (Fig. 2).
Interestingly, the fibroblasts generated from heterozygous ani-
mals showed a more than 50% reduction in LTBP-1 expression.
The absence of LTBP-1 resulted in a bone phenotype that
may relate to TGF-β functionality. To demonstrate potential
alterations in biological activity of TGF-β, we comparatively
analyzed the activation of HSC from Wt and Ltbp-1 nulls in
Table 4
Classification of up- and downregulated genes in activated Wt and Ltbp1−/− HSC
Gene
symbol
GenBank
accession no.
Gene Mean activated
WT/Ltbp1−/− HSC
δ Mean activated/
quiescent WT HSC
Marker for
activation/quiescence
ltbp1 NM_019919 Latent transforming growth factor-β binding protein-1 2.61 0.09 1.89 ACT
ptgs2 NM_011198 Prostaglandin-endoperoxide synthase 2 1.99 0.03 14.92 ACT
tm4sf1 NM_008536 Transmembrane 4 superfamily member 1 1.86 0.01 20.01 ACT
mmp13 NM_008607 Matrix metallopeptidase 13 1.83 0.03 39.32 ACT
f3 NM_010171 Coagulation factor III 1.81 0.09 1.58 ACT
mmp10 NM_019471 Matrix metallopeptidase 10 1.76 0.03 19.44 ACT
thbd NM_009378 Thrombomodulin 1.74 0.03 20.21 ACT
plaur NM_011113 Plasminogen activator, urokinase receptor 1.61 0.03 1.48 NN
thbs3 NM_013691 Thrombospondin 3 1.58 0.02 3.33 ACT
mapk6 NM_015806 Mitogen-activated protein kinase 6 1.55 0.04 4.49 ACT
pgf NM_008827 Placental growth factor 1.53 0.03 6.32 ACT
ccnd1 NM_007631 Cyclin D1 1.51 0.04 4.09 ACT
col18a1 NM_009929 Procollagen, type XVIII, α1 −1.51 0.28 −1.43 NN
rgs3 NM_019492 Regulator of G protein signaling 3 −1.51 0.05 −1.67 Q
col6a2 NM_146007 Procollagen, type VI, α 2 −1.52 0.09 −1.92 Q
rgs4 NM_009062 Regulator of G protein signaling 4 −1.53 0.17 −2.15 Q
thbs2 NM_011581 Thrombospondin 2 −1.53 0.04 1.44 NN
c1s NM_144938 Complement component 1, s subcomponent −1.53 0.30 −8.70 Q
socs3 NM_007707 Suppressor of cytokine signaling 3 −1.54 0.23 −4.08 Q
mcam NM_023061 Melanoma cell adhesion molecule −1.54 0.07 −1.72 Q
hlx1 NM_008250 h2.0-like homeo box 1 (Drosophila) −1.55 0.18 −2.60 Q
adamts2 NM_175643 A disintegrin-like and metallopeptidase
(reprolysin type) with thrombospondin type 1 motif, 2
−1.63 0.06 −2.02 Q
mgst1 NM_019946 Microsomal glutathione S-transferase 1 −1.64 0.07 4.52 ACT
col1a2 NM_007743 Procollagen, type I, α2 −1.65 0.07 −1.43 NN
p2ry14 NM_133200 Purinergic receptor p2y, G protein coupled, 14 −1.66 0.05 4.94 ACT
ifit1 NM_008331 Interferon-induced protein with tetratricopeptide repeats 1 −1.71 0.29 −3.85 Q
gata4 NM_008092 Gata binding protein 4 −1.75 0.24 −1.43 Q
itgb5 NM_010580 Integrin β5 −1.78 0.06 −1.02 NN
bgn NM_007542 Biglycan −1.81 0.01 −1.92 Q
prelp NM_054077 Proline arginine-rich end leucine-rich repeat −1.92 0.31 −1.89 Q
hgf NM_010427 Hepatocyte growth factor −1.92 0.11 −4.35 Q
mfap2 NM_008546 Microfibrillar-associated protein 2 −1.95 0.40 −1.12 NN
il6st NM_010560 Interleukin 6 signal transducer −1.96 0.19 −3.28 Q
nos3 NM_008713 Nitric oxide synthase 3, endothelial cell −1.96 0.41 −2.60 Q
egr1 NM_007913 Early growth response 1 −1.98 0.51 −8.70 Q
col6a1 NM_009933 Procollagen, type VI, α1 −2.12 0.12 −4.65 Q
clu NM_013492 Clusterin −2.15 0.08 −1.77 Q
cmkor1 NM_007722 Chemokine orphan receptor 1 −2.36 0.98 −1.14 NN
lum NM_008524 Lumican −2.42 0.18 −10.00 Q
lrat NM_023624 Lecithin–retinol acyltransferase
(phosphatidylcholine-retinol-O-acyltransferase)
−3.39 0.44 −16.67 Q
Ratios are indicated as fold change. Ratios b1 are given as negative reciprocal values. Mean: mean values of the measured expression ratios and standard deviation δ is
calculated from three independent hybridizations of activated WT/Ltbp1−/− HSC (consecutive array numbers 85, 90, 33). Mean values for the hybridizations of
activated/quiescent WT HSC are calculated from 2 independent experiments (consecutive array numbers 40 and 42). Due to nb3 δ-values are not denoted for latter
experiments. Abbreviations used are: ACT, marker for activation; NN, dependence on activation status presently unknown; Q, marker for quiescence.
44 F. Drews et al. / Biochimica et Biophysica Acta 1783 (2008) 34–48vitro, a process that is mainly triggered by the fibrogenic action
of TGF-β1 [38]. Although it is obvious that in vitro conditions
cannot exactly mimic the pathological conditions that lead to
cellular activation in vivo, a proteome analysis of rat HSC
showed that 60% of the analyzed proteins showed similar
changes during activation in vivo and in vitro [39]. So far,
previous microarray studies have only gathered data on human
HSC transdifferentiation or mouse HSC comparing cells
cultured for 3 days, referred to as quiescent cells, with fully
transdifferentiated cells after 3 passages in vitro [40]. Therefore,
the microarray data set generated in the present study provides
for the first time an insight into the changes of gene expres-
sion of fresh primary mouse HSC cultured for only 1 day andactivated cells after 6 days of culturing. The markers identified
are well in agreement with so far published data on gene
expression changes induced by HSC activation. In addition,
many genes could be identified that had so far not been
described to be expressed in activated HSC.
In the present study, the comparison of the gene expression of
quiescent and activated HSC was subsequently decisive to
classify the differential gene expression of Ltbp-1−/− and Wt
HSC. Although only marginal expression differences were
found, our findings suggest that Ltbp-1-deficient cells have a
decreased tendency of spontaneous transdifferentiation in vitro
indicating that Ltbp-1 is of relevance in HSC during the process
of “activation” and the velocity of cell alteration. On the level of
Table 5
Regulation of TGF-β-associated genes in all experiments
Gene
symbol
GenBank accession no. Gene Mean activated
WT/Ltbp1−/− HSC
δ Mean activated/
quiescent WT HSC
Marker for activation/
quiescence
ltbp1 NM_206958
NM_019919
Latent transforming growth factor-β binding protein-1 2.61 0.09 1.89 KO/ACT
ltbp2 NM_013589 Latent transforming growth factor-β binding protein 2 −1.38 0.12 1.40 NN
ltbp3 NM_008520 Latent transforming growth factor-β binding protein 3 −1.03 0.13 1.54 ACT
ltbp4 NM_175641 Latent transforming growth factor-β binding protein 4 −1.03 0.02 −50.00 Q
tgfb1 NM_011577 Transforming growth factor, β1 −1.16 0.00 −1.79 Q
tgfb3 NM_009368 Transforming growth factor, β3 1.03 0.09 1.50 ACT
tgfb2 NM_009367 Transforming growth factor, β2 −1.12 0.07 2.60 ACT
tgfa NM_031199 Transforming growth factor α 1.02 0.04 −1.09 NN
acvr1 NM_007394 Activin A receptor, type 1 −1.09 0.06 −1.20 NN
acvr2a NM_007396 Activin receptor IIa 1.08 0.06 −2.67 Q
acvrl1 NM_009612 Activin A receptor, type II-like 1 −1.12 0.21 2.09 ACT
tgfbr2 NM_009371
NM_029575
Transforming growth factor, β receptor type II −1.37 0.13 −1.04 NN
fstl1 NM_008047 Follistatin-like 1 −1.45 0.04 10.72 ACT
foxh1 NM_007989 Forkhead box h1 1.03 0.07 1.41 NN
actb NM_007393 Actin, β, cytoplasmic 1.28 0.03 −1.80 Q
Ratios are indicated as fold change. Ratios b1 are given as negative reciprocal values. Mean: mean values of the measured expression ratios and standard deviation δ is
calculated from three independent hybridizations of activated WT/Ltbp1−/− HSC (consecutive array numbers 85, 90, 33). Mean values for the hybridizations of
activated/quiescent WT HSC are calculated from 2 independent experiments (consecutive array numbers #40 and #42). Due to nb3 δ-values are not denoted for latter
experiments. Abbreviations used are: ACT, marker for activation; NN, dependence on activation status presently unknown; Q, marker for quiescence.
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TGF-β isoforms was observed in Ltbp-1−/− HSC. Nonetheless,
without the complex ECM organization found in the liver,
LTBP-1 is probably dispensable for the auto- and paracrine
TGF-β signalling loops. During culturing, traces of TGF-β
brought in by the serum might additionally compensate for en-
dogenous TGF-β secretion in Ltbp-1−/− cells resulting in only
marginal changes in gene transcription in HSC deficient for
LTBP-1.
Nevertheless, the array data independently confirmed the
results of the in vivo study demonstrating a decreased fibrogenic
potential of Ltbp-1 nulls using a cholestatic model of hepatic
fibrogenesis. Although, in both, normal controls and Ltbp-1
nulls, the liver-specific blood parameters indicating liver dam-
age were increased after ligature of the common bile duct, the
TGF-β-dependent deposition of collagen fibers and expression
of α-SMAwere decreased in the knockout animals. The absence
of LTBP-1 may reduce the overall concentration of biologically
active TGF-β during the fibrogenic response which could be
supported by the microarray expression profile. Previous re-
ports have demonstrated that the expression level of LTBP-1 is
decreased while TGF-β is increased during hepatic injury in
humans, suggesting that in late stages of liver injury, TGF-β1
can be synthesized or secreted independently from LTBP-1
[41]. We have not yet tested the link between LTBP-1 and TGF-
β1 synthesis/secretion during carcinoma formation in the
animals generated in this study. However, it is reasonable that
the observed linkage of LTBP-1 and TGF-β secretion might be
masked in the setting of diseases that are associated with
cellular necrosis and revascularisation.
The microarray analysis further revealed that the expression
of principally components of the ECM such as decorin, lumican
or biglycan was increased in HSC of the nulls, again reflecting
the significant contribution of LTBP-1 to the formation andcomposition of the hepatic ECM. However, the results might be
specific for the mouse systems since previous studies have
shown that the steady-state levels of decorin increases during
primary culture in rats [42]. Nevertheless, the gene Lrat,
encoding for the lecithin:retinol acetyltransferase (LRAT) that is
a central mediator of the vitamin A metabolism in HSC [43,44]
is significantly upregulated in cultured HSC of the nulls.
Interestingly, LRAT nulls have reduced amounts of oil droplets
in HSC [45], suggesting that this enzyme is necessary to keep
the quiescent state and again demonstrating that HSC taken
from Ltbp-1 nulls are less prone to the fibrogenic response [46].
It is most likely that the expression of these genes is directly
linked to an overall reduced TGF-β1 activity. In our transfection
experiments (Fig. 7), we confirmed previous results showing
that the intracellular processing or secretion of TGF-β in CHO
cells is enhanced when LTBP-1 is present [47]. Reversely, it is
tempting to speculate that the absence of LTBP-1 will result in
an overall reduced activity of biological active TGF-β in HSC.
As a consequence, the cellular activation of these cells is de-
celerated which correlated to the expression of genes typically
increased during this process (see Table 4). However, we have
not comparatively measured the concentration of TGF-β1 in
blood or tissues of Wt or Ko animals which would be ultimately
necessary to prove our speculations. Unfortunately, these mea-
surements from complex biological materials are technically
demanding hampering their precise quantification [48].
The Ltbp-1 nulls are characterized by mild alterations in the
bones that are visible in significant shortenings of the femur, the
tibia/fibula and also the metatarsal. More pronounced bone
abnormalities were reported for mice lacking Ltbp-3 [24,25]. It
was also assumed, that TGF-β is important for long bone
physiology. Due to this background and the proposed functional
overlap of Ltbp-1 and -3, the observed alterations of Ltbp-1−/−
mice were understandable. In line with these findings, it was
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reduction in bone size and cranial ossification [49], suggesting
that TGF-β isoforms in general might have a essential role in
skeletal induction and growth. The loss of TGF-β1 results in aFig. 7. LTBP-1 enhances TGF-β1 secretion. (A) CHO cells were transfected
with an expression vector encoding FLAG-tagged TGF-β1 alone or in
combination with an expression vector for hLTBP-1-S, GFP, or empty vector
(pcDNA). Cell extracts and supernatants were taken after 48 h and probed with
an antibody specific for the FLAG epitope. The signals for pro-TGF-β served as
an internal loading control. (B) The functionality of the hLTBP-1 expression
vector used in panel Awas demonstrated by Western blot using antibody Ab-39.
The expressed human LTBP-1S protein was detectable as a band with an
apparent molecular weight of ∼180,000.
Fig. 6. Confirmation of microarray data. (A) Total RNA isolated from HSC of
Wt and Ltbp-1 nulls were subjected to RT-PCR and analyzed for expression of
interferon-induced protein with tetratricopeptide repeats 1 (IFIT), clusterin
(CLU), lecithin-retinol acyltransferase (LRAT), prostaglandin synthase
(PTGS2), latent TGF-β binding protein-1 (Ltbp-1), G-protein-coupled receptor
(RDC1), and hepatocyte growth factor (HGF). The housekeeping gene encoding
for β-actin (ACTB) and ribosomal protein S6 (RPS6) were taken as controls. The
position of nucleotide size markers are indicated on the right. Primers used
for amplification and fragment sizes are listed in Supplementary Table 1.
(B) Northern blot analysis was performed on 10 μg total RNA isolated from
embryonic fibroblasts with Wt (+/+) and Ko (−/−) genotype. The blot was
hybridized with each 32P-labelled probes generated from subcloned microarray
gene fragments highly specific for neutrophil gelatinase-associated lipocalin
(LCN2) and serine protease HTRA1 (PRSS11). As internal loading controls, the
28S rRNA, 18S rRNA, and signals obtained after hybridization with a GAPDH-
specific probe are displayed. The blots were exposed for 10 (LCN2) or 14 days
(PRSS11).wasting syndrome about 20 days after birth that is accompanied
by a multifocal, mixed inflammatory cell response and tissue
necrosis, leading to organ failure and death [50]. In contrast, the
lack of LTBP-1 does not interfere with the general viability
suggesting that LTBP-1 is only one factor influencing cellular
secretion of TGF-β1. Possibly, other factors including LTBP2–4
are able to compensate for some endogenous functions of LTBP-1.
The most conspicuous observation was the distorted facial
structure that was statistically confirmed by X-ray analysis.
TGF-β is well known to influence the proliferation and differ-
entiation of cells. Therefore, it was not surprising that the loss of
one of their binding proteins influences the overall growth of
mice tissues especially because bone deformations were pre-
viously published for the very similar Ltbp-3−/− mice [24,25]
and a direct relationship between TGF-β and bone homeostasis
were monitored before [51]. A compensatory influence of the
Ltbp-1 Ko on the expression of Ltbp-3 could be excluded by
our microarray data and by Northern blot analysis. The reason
for the skull deformation in Ltbp-1−/− is unclear. However,
because of the important role of TGF-β1 in bone resorption and
formation a reduced level of biological active TGF-β1 might be
causative for these alterations. Lack of TGF-β1 for instance was
previously shown to cause a diminished longitudinal bone
growth rate and more fragile and less elastic bones (reviewed in
[52]). Likewise, the rare Camurati–Engelmann disease that is
47F. Drews et al. / Biochimica et Biophysica Acta 1783 (2008) 34–48caused by mutations mainly in the LAP is correlated with bone
disorders and alterations of bone density. Therefore, we further
analyzed the bone density in thin slides of mandible in the Ltbp-
1−/− mice. However, we found no significant differences between
control animals and Ltbp-1−/−mice in thin slides of the mandibles
that were indicated by the unchanged quota of trabecel (Table 1).
Interestingly, theLtbp-3−/−mice have a high bonemass phenotype
due to a defect in bone resorption [29] suggesting that the LTBP-1
and LTBP-3 proteins function differently during the development
of bones.While LTBP-1 shows a strong interaction with the ECM
[8] especially with fibrillin-containing microfibrils particularly in
bone cells [52], the loss of LTBP-1may induce alterations in ECM
expression and deposition that subsequently induce abnormal
bone formation. The results from the microarray analysis
supported this hypothesis. Recently, Sivakumar and coworkers
demonstrated the active participation of LTBP-1 in the dynamic
assembly and reorganization of the ECM in osteoblasts [53].
Future studies in double knockouts (Ltbp-1/Ltbp-3 and Ltbp-1/
Ltbp-4) will definitively provide more insights in understanding
the precise functions of individual LTBPs in ECMproduction and
regulating of TGF-β bioavailability.
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